Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indoximod and Temozolomide for Pediatric Brain Tumors
NCT02502708Phase 1Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Oct 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of indoximod in glioblastoma (GBM), glioma, Gliosarcoma (GS) and 4 more (5 arms), sponsored by Lumos Pharma, Inc. Primary endpoints: Incidence of regimen limiting toxicities at 28 days, Objective Response Rate at 3 years and 1 more. Started Oct 2015; status: completed.
02
Drugs
indoximod
03
Conditions
glioblastoma (GBM)gliomaGliosarcoma (GS)ependymomamedulloblastoma
Beyond the preview
Go deeper on NCT02502708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502708.